Which? investigation exposes gaps in online weight loss jab prescribing

A consumer group investigation has found that online pharmacies are applying prescribing rules for GLP-1 weight loss drugs inconsistently. The findings raise questions about how robustly patient information is being verified before dispensing takes place.

What happened

Which? ran an investigation into how online pharmacies handle prescribing and dispensing of GLP-1 medications used for weight loss. The probe found significant variation in how different services interpret and apply prescribing rules for these drugs. Some online pharmacies were found to have supplied the medications without adequately checking the information provided by patients.

The investigation points to a pattern of inconsistent practice across the online pharmacy sector, rather than a single isolated failure.

Why it matters

GLP-1 receptor agonists — drugs like semaglutide and liraglutide — have seen a sharp rise in demand over the past two years. That demand has driven growth in online prescribing services offering weight management programmes. But with growth comes pressure on clinical governance, and this investigation suggests that pressure is showing.

For anyone working in or around pharmacy, this matters on a practical level. Dispensing any prescription medicine carries a professional and legal responsibility. The pharmacist's role in the supply chain isn't just to count and label — it includes checking that the clinical and logistical information supporting a prescription is sound. When patient details go unverified, that check fails.

The Which? findings also sit within a broader regulatory conversation. The GPhC has published guidance on the standards expected of online pharmacy services, and the question of whether those standards are being met consistently is one that the regulator, NHS England, and the MHRA all have an interest in. An investigation of this kind tends to accelerate scrutiny rather than resolve it.

There's a wider public safety dimension too. GLP-1 drugs are not risk-free. They carry a side-effect profile that includes gastrointestinal effects, pancreatitis risk, and contraindications in certain patient groups including those with a personal or family history of medullary thyroid carcinoma. Prescribing based on inaccurate or unverified information puts patients in those risk categories in a genuinely difficult position — they may receive a medicine that should never have been prescribed to them.

GPhC exam relevance

The GPhC assessment tests candidates on the standards that underpin safe and effective pharmacy practice. This story connects directly to several of those areas.

The GPhC's standards for registered pharmacies require that pharmacies have effective governance arrangements in place and that the safety and quality of services are maintained. The standards for pharmacists place a duty on registrants to act in patients' best interests and to take responsibility for the clinical appropriateness of what they supply.

Online and distance-selling pharmacies operate under the same legal and professional framework as bricks-and-mortar pharmacies. Distance doesn't reduce the pharmacist's duty — if anything, it places more weight on the systems used to verify patient information, since the pharmacist cannot see the patient directly.

For the assessment, be confident on:

• The pharmacist's responsibility in the dispensing process, including clinical screening
• What the GPhC standards for registered pharmacies require in terms of governance
• The conditions and contraindications relevant to GLP-1 receptor agonists
• The distinction between a valid prescription and one that should prompt further checks

Scenario-based questions in this area often ask what a pharmacist should do when information provided with a prescription appears incomplete, inconsistent, or unverifiable. The answer nearly always requires the pharmacist to pause supply and seek clarification — not to dispense and hope.

What's next

Watch for a response from the GPhC or NHS England following the Which? publication. Investigations like this one often prompt regulatory letters to the sector, updated guidance, or in more serious cases, formal investigations into named services.

If you're doing a placement or working in an online pharmacy setting, it's worth familiarising yourself with how your service verifies patient-submitted information and what the escalation pathway looks like when something doesn't add up. That process should be documented and accessible.

The GLP-1 prescribing space is likely to remain under scrutiny. MHRA has already taken action on unlicensed compounded versions of semaglutide, and the appetite for further oversight — from both the regulator and consumer groups — isn't going away.

Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/clinical/online-pharmacies-named-in-weight-loss-jab-investigation-MVKT2NTNMVB5RMXVCGQPECMVRE/